EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 / No 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1022-1025 References
Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1022 - 1025
Section Les anticorps dans les maladies autres qu’oncologiques
DOI https://doi.org/10.1051/medsci/2019202
Published online 06 January 2020
  1. Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation of PTCA to improve long-term outcome with abciximab GPIIb/IIIa receptor blockade. 1998; 32: 1619–23. [Google Scholar]
  2. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429–35. [CrossRef] [PubMed] [Google Scholar]
  3. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016 ; 374: 511–522. [Google Scholar]
  4. Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2018 ; 2018: 539–547. [Google Scholar]
  5. Lebozec K, Jandrot-Perrus M, Avenard G, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks. MAbs. 2017 ; 9: 945–958. [CrossRef] [PubMed] [Google Scholar]
  6. Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17. [PubMed] [Google Scholar]
  7. Wallisch M, Tucker EI, Lorentz CU, et al. The anti-factor XII antibody AB052 is antithrombotic without hemostatic impairment in a primate model of extracorporeal membrane oxygenation. Blood 2017 ; 130: 236. [Google Scholar]
  8. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009 ; 113: 936–944. [Google Scholar]
  9. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012 ; 18: 1570–1574. [CrossRef] [PubMed] [Google Scholar]
  10. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017 ; 377: 809–818. [Google Scholar]
  11. Young G, Callaghan M, Dunn A, et al. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol 2018 ; 11: 835–846. [PubMed] [Google Scholar]
  12. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? 2017; 130: 2463–8. [Google Scholar]
  13. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 2016 ; 36: 9–14. [CrossRef] [PubMed] [Google Scholar]
  14. Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012 ; 119: 5871–5878. [Google Scholar]
  15. Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost 2018 ; 16: 2184–2195. [CrossRef] [PubMed] [Google Scholar]
  16. Cardinal M, Kantaridis C, Zhu T, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost 2018 ; 16: 1722–1731. [CrossRef] [PubMed] [Google Scholar]
  17. Augustsson C, Svensson A, Kjaer B, et al. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain. J Thromb Haemost 2018 ; 16: 893–904. [CrossRef] [PubMed] [Google Scholar]
  18. Gu JM, Zhao XY, Schwarz T, et al. Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys. AAPS J 2017 ; 19: 1186–1195. [CrossRef] [PubMed] [Google Scholar]
  19. Susen S, Rauch A, Van Belle E, et al. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost 2015 ; 13: 1757–1767. [CrossRef] [PubMed] [Google Scholar]
  20. Rauch A, Legendre P, Christophe OD, et al. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thromb Haemost 2014 ; 112: 1014–1023. [CrossRef] [PubMed] [Google Scholar]
  21. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. N Engl J Med 2013 ; 121: 3554–3562. [Google Scholar]
  22. Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015 ; 373: 511–520. [Google Scholar]
  23. Pollack CV, Jr., Reilly PA, van Ryn J. Idarucizumab for dabigatran reversal - full cohort analysis. 2017 ; 377: 431–441. [Google Scholar]
  24. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015 ; 372: 196–197. [Google Scholar]
  25. Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood 2015 ; 125: 3484–3490. [Google Scholar]
  26. Muczynski V, Casari C, Moreau F, et al. A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. Blood 2018 ; 132: 1193–1197. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.